ABTAbbott Laboratories presents a balanced investment profile with strong fundamentals in the healthcare sector. While its valuation is moderate and technical indicators show mixed signals, its consistent dividend and diversified product portfolio offer stability. The company is well-positioned within established healthcare trends.
Abbott operates in stable, long-term growth sectors of healthcare. Its diverse product segments (diagnostics, medical devices, nutrition, established pharmaceuticals) provide resilience against specific market shifts. Emerging trends in personalized medicine and remote diagnostics are areas of opportunity.
Abbott Laboratories exhibits robust financial health with strong profitability, consistent revenue growth, and a healthy balance sheet. Its earnings have generally met or exceeded expectations, and it maintains a solid dividend payout.
The stock is trading below its 52-week high and shows mixed signals across different timeframes. While longer-term trends suggest underlying strength, short-term indicators point to a consolidating or slightly bearish sentiment.
| Factor | Score |
|---|---|
| Healthcare Demand | 85 |
| Medical Device Innovation | 70 |
| Diagnostic Capabilities | 80 |
| Nutritional Products | 75 |
| Pharmaceutical Pipeline | 50 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 95 |
| Growth | 60 |
| Balance Sheet Health | 75 |
| Cash Flow | 85 |
| Dividend | 70 |
| Earnings Performance | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 50 |
| Moving Averages (1D) | 40 |
| Short-term Oscillators (15m) | 70 |
| Volume Analysis (1D) | 50 |
| Support & Resistance | 70 |
Consistent EPS Beat
The company has exceeded EPS estimates in the last 4 quarters, with positive surprises ranging from 0.1% to 26.85%, indicating robust earnings generation.
Attractive P/E Ratio
The trailing P/E ratio of 15.76 is lower than the industry average, suggesting the stock may be undervalued relative to its earnings.
Elevated Quarterly P/E Ratio
The first quarter 2025 P/E ratio of 172.6 is exceptionally high, potentially indicating overvaluation or significant investor expectations for future growth.
Slowing Revenue Growth
While annual revenue in 2024 was strong, the trend in quarterly revenue shows a decrease from Q4 2024 ($10.97B) to Q1 2025 ($10.36B), potentially signaling a slowdown.
July 2025
15
Ex-Dividend Date
August 2025
15
Next Dividend Date
October 2025
15
Next Earnings Date
H: $1.32
A: $1.30
L: $1.28
H: 11.50B
A: 11.40B
L: 11.22B
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
141.62 USD
The 39 analysts offering 1 year price forecasts for ABT have a max estimate of 159.00 and a min estimate of 120.12.